Biotechnology News and Research

RSS

Statement on Ebola epidemic

The Ebola virus is spreading rapidly and to an unexpected extent. The outbreak does not follow the patterns experienced in the past and the virus shows a new disease dynamic in regions, where it has never been recorded before. For this reason, the German National Academy of Sciences Leopoldina, acatech – the German Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities have presented a statement on the Ebola epidemic today.

16 Oct 2014

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.

16 Oct 2014

Scientists receive BBSRC funding to study how neural stem cells differ from each other

A team of scientists led by a researcher from Plymouth University has received funding of more than £400,000 from the Biotechnology and Biological Sciences Research Council to investigate how neural stem cells differ from each other. The study's findings could hold the key to the future use of neural stem cells in treatments to eradicate neurological conditions such as dementia and brain tumours.

15 Oct 2014

PhRMA launches new website to educate consumers about ABCs of health coverage

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched Access Better Coverage.org, a new website designed to educate consumers about the ABCs of health coverage and access to prescription medicines.

14 Oct 2014

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness.

14 Oct 2014

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland.

14 Oct 2014

FDA approves new hepatitis C drug, Harvoni

Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients.

14 Oct 2014

New surface coating for medical devices prevents blood from clotting

From joint replacements to cardiac implants and dialysis machines, medical devices enhance or save lives on a daily basis. However, any device implanted in the body or in contact with flowing blood faces two critical challenges that can threaten the life of the patient the device is meant to help: blood clotting and bacterial infection.

13 Oct 2014

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

European experts publish common vision of priorities for marine research

Some 340 European scientists, policy-makers and other experts representing 143 organizations from 31 countries spoke with one voice today, publishing a common vision of today's most pressing marine-related health and economic threats and opportunities.

9 Oct 2014

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis.

9 Oct 2014

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.

9 Oct 2014

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

A fundamental theory about how our thymus educates our immune police appears to be wrong, scientists say.

9 Oct 2014

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents.

9 Oct 2014

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.

8 Oct 2014

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

8 Oct 2014

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).

8 Oct 2014

Low sexual desire among women can be treatable

Low sexual desire is common among both pre- and post-menopausal women. It can cause personal distress, harm relationships, and have a negative impact on body image and self confidence. Yet few women seek medical care for this condition, and the reasons are explored in a timely article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

8 Oct 2014

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic.

8 Oct 2014

Early potty training linked to increased risk of developing daytime wetting problems later

Children who start toilet training before age 2 have a three times higher risk of developing daytime wetting problems later, according to new research at Wake Forest Baptist Medical Center.

8 Oct 2014

Biotechnology News and Research

Statement on Ebola epidemic

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

Scientists receive BBSRC funding to study how neural stem cells differ from each other

PhRMA launches new website to educate consumers about ABCs of health coverage

Research opens door to potential new treatments for peripheral artery disease

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

FDA approves new hepatitis C drug, Harvoni

New surface coating for medical devices prevents blood from clotting

First study of promising Ebola vaccine commenced in West Africa

European experts publish common vision of priorities for marine research

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

HemoShear completes first-phase development of novel cancer drug discovery platform

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

Researchers are developing compounds to combat causative agents of periodontitis

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

Low sexual desire among women can be treatable

C3BS inks preferred access agreement with Mayo Clinic

Early potty training linked to increased risk of developing daytime wetting problems later

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News